➤ Long-term data on treatment for neuropathic corneal pain ➤ European agency issues positive opinion for low-dose atropine formulation ➤ Study: semaglutide use associated with increased risk of NAION ➤ Company news ➤ ASCRS news and events
➤ ASCRS advocacy helps protect MIGS coverage ➤ FDA approves generic loteprednol etabonate ophthalmic suspension ➤ Orphan Drug Designation granted for corneal endothelial cell substitute ➤ Positive results in Phase 2 clinical trial for contact lens discomfort ➤ First patient visits ➤ Acquisition news ➤ Complimentary access to video journal ➤ ASCRS news and events
➤ Bausch + Lomb acquires AcuFocus ➤ Study: novel drug delivery system sees less inflammation with preserved drops ➤ Meibomian gland atrophy common among cataract patients, study finds ➤ mRNA technology investigated for gene therapy to treat blindness ➤ Studies find new bionic vision system offers improved outcomes ➤ ASCRS news and events
➤ FDA accepts NDA for pupil dilation spray ➤ NDA for new glaucoma drug accepted ➤ PMA application submitted to FDA for new IOL ➤ Data report: 12-month efficacy seen from single mechanical MGD treatment ➤ Acquisition of company developing drugs for rare ophthalmic diseases ➤ ASCRS news and events
➤ Results from pivotal amblyopia trial ➤ Phase 2 clinical program for third-generation keratoconus treatment ➤ Study compares tolerability of standard drop vs. novel drug delivery device ➤ Phase 3 clinical studies for investigational presbyopia drop complete ➤ Orphan drug designation granted for fungal keratitis treatment ➤ Full rights regained for investigational dry AMD therapy ➤ ASCRS news and events